A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole; Everolimus; Exemestane; Fulvestrant; Letrozole; Loperamide; Pertuzumab; Samotolisib; Tamoxifen; Trastuzumab
- Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 28 Aug 2024 Planned End Date changed from 31 Dec 2024 to 1 Dec 2024.
- 10 Oct 2023 Planned End Date changed from 20 Sep 2023 to 31 Dec 2024.
- 08 Aug 2022 Planned End Date changed from 28 Oct 2023 to 20 Sep 2023.